We Don't Need Patent Monopolies to Finance Vaccine Research

It is amazing that a lengthy piece in the NYT discussing the high cost of new vaccines and the efforts of companies to promote them never discussed the possibility of alternatives to patent monopolies as a way to finance the research. Until recent years, most vaccines actually were developed with public funding, so obviously it is possible.

If the research were paid with public funding, then vaccines would be cheap since they would all be generics. And, there would not be a problem with compa...